Developments in predictive biomarkers for hepatocellular carcinoma therapy

References

• Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: editors, Adami HO, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. 2nd ed. New York: Oxford University Press; 2008.
   Google Scholar
• World Health Organization, I.A.f.R.o.C. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx.
   Google Scholar
• Daher S, Massarwa M, Benson AA, et al. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol. 2018;6(1):69–78.
   PubMed Web of Science ®Google Scholar
• Longo V, Gnoni A, Casadei Gardini A, et al. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget. 2017;8(20):33897–33910.
   PubMedGoogle Scholar
• Tovoli F, Casadei-Gardini A, Benevento F, et al. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Dig Liver Dis. 2019;51(8):1067–1073.
   PubMedGoogle Scholar
• Hato T, Zhu AX, Duda DG. Rationally combining anti‐VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016;8:299–313.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2018;36(suppl 15):4076A.
   Web of Science ®Google Scholar
• Stein S, Pishvaian MJ, Lee MS, et al. Safety and clinical activity of 1L atezolizumab and bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol. 2018;36(suppl 15):4074A.
   Web of Science ®Google Scholar
• Xu JM, Zhang Y, Jia R, et al. Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial. J Clin Oncol. 2018;36(suppl 15):4075A.
   Web of Science ®Google Scholar
• Maggs JR, Suddle AR, Aluvihare V, et al. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1113–1134.
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation french study group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.e3. quiz e14-5.
   PubMed Web of Science ®Google Scholar
• Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552–559.
   PubMed Web of Science ®Google Scholar
• Schraiber Ldos S, de Mattos AA, Zanotelli ML, et al. Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma. Medicine (Baltimore). 2016;95:e2478.
   PubMed Web of Science ®Google Scholar
• Xu X, Ke QH, Shao ZX, et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54:385–388.
   PubMed Web of Science ®Google Scholar
• Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598–609.
   PubMed Web of Science ®Google Scholar
• Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: hangzhou experiences. Transplantation. 2008;85:1726–1732.
   PubMed Web of Science ®Google Scholar
• Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49:832–838.
   PubMed Web of Science ®Google Scholar
• Grąt M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–2707.
   PubMed Web of Science ®Google Scholar
• Lai Q, Avolio AW, Manzia TM, et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant. 2012;26:E125–E131.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kwon CH, Joh JW, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc. 2014;46:726–729.
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Tabrizian P, Najjar M, et al. Is it time to abandon the milan criteria?: results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies. Ann Surg. 2018;268:690–699.
   PubMed Web of Science ®Google Scholar
• Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999;94(3):650–654.
   PubMed Web of Science ®Google Scholar
• Lai Q, Iesari S, Levi Sandri GB, et al. Des-gamma-carboxy prothrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysis. Int J Biol Markers. 2017;32(4):e370–e374. Published 2017 Oct 31.
   PubMed Web of Science ®Google Scholar
• Cui X, Li Z, Gao PJ, et al. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14(2):157–163.
   PubMed Web of Science ®Google Scholar
• Wang YL, Zhu ZJ, Teng DH, et al. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012;18(19):2408–2414.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen Z, Zhu Z, et al. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon. 2011;11(3):195–199.
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55–60.
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250:141–151.
   PubMed Web of Science ®Google Scholar
• Najjar M, Agrawal S, Emond JC, et al. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:17–28.
   PubMed Web of Science ®Google Scholar
• Xu ZG, Ye CJ, Liu LX, et al. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. Biomark Med. 2018;12:189–199.
   PubMed Web of Science ®Google Scholar
• Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–1360.
   PubMed Web of Science ®Google Scholar
• Zhang W, Kim R, Quintini C, et al. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2015;21(1):101–111.
   PubMed Web of Science ®Google Scholar
• Xue F, Shi S, Zhang Z, et al. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol Lett. 2018;15(4):5481–5488.
   PubMed Web of Science ®Google Scholar
• Wang S, Zheng Y, Liu J, et al. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation. J Investig Med. 2018;66(5):1,6.
   PubMed Web of Science ®Google Scholar
• Akinobu T, Kazuhide Y. Control of oxidative stress in hepatocellular carcinoma: helpful or harmful? World J Hepatol. 2015 May 8;7(7):968–979.
   PubMed Web of Science ®Google Scholar
• Dundar HZ, Aksoy F, Aksoy SA, et al. Overexpression of miR-21 is associated with recurrence in patients with Hepatitis B virus-mediated hepatocellular carcinoma undergoing liver transplantation. Transplant Proc. 2019;51(4):1157–1161.
   PubMed Web of Science ®Google Scholar
• Xie QY, Almudevar A, Whitney-Miller CL, et al. a microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. BMC Med Genomics. 2016;9:18.
   PubMed Web of Science ®Google Scholar
• Guo D, Gu D, Wang H, et al. Radiomics analysis enables recurrence prediction for hepatocellular carcinoma after liver transplantation. Eur J Radiol. 2019;117:33–40.
   PubMed Web of Science ®Google Scholar
• Chang SK, Hlaing WW, Yu RQ, et al. Value of alpha-fetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Singapore Med J. 2012;53(1):32–35.
   PubMed Web of Science ®Google Scholar
• Shirabe K, Takenaka K, Gion T, et al. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol. 1997;64:143–146.
   PubMed Web of Science ®Google Scholar
• Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73.
   PubMed Web of Science ®Google Scholar
• Lee HH, Uen YH, Tian YF, et al. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1562–1569.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bai Y, Xu L, et al. Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. Hepatol Int. 2019 Nov;13(6):715–725.
   Web of Science ®Google Scholar
• Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–305.
   PubMed Web of Science ®Google Scholar
• Itoh S, Yugawa K, Shimokawa M, et al. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open. 2019;3(4):500–508.
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971–979.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship With clinical and pathological features. Hepatology. 2016;64(6):2038–2046.
   PubMed Web of Science ®Google Scholar
• Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246–254.
   PubMed Web of Science ®Google Scholar
• Semaan A, Dietrich D, Bergheim D, et al. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Arch. 2017;470(2):185–196.
   PubMed Web of Science ®Google Scholar
• Hu K, Wang ZM, Li JN, et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol. 2018;11(2):552–558.
   PubMed Web of Science ®Google Scholar
• Gu X, Gao XS, Xiong W, et al. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. Onco Targets Ther. 2016 [Published 2016 Aug 2];9:4805–4813.
   PubMed Web of Science ®Google Scholar
• Ni XC, Yi Y, Fu YP, et al. Prognostic value of the modified glasgow prognostic score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine (Baltimore). 2015;94(36):e1486.
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The glasgow prognostic score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013 [Published 2013 Feb 2];13:52.
   PubMed Web of Science ®Google Scholar
• Chan AW, Chan SL, Wong GL, et al. Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. Ann Surg Oncol. 2015;22(13):4138–4148.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li C, Wen T, et al. Postoperative prognostic nutritional index predicts survival of patients with hepatocellular carcinoma within milan criteria and hypersplenism. J Gastrointest Surg. 2017 Oct;21(10):1626–1634.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439–1445.
   PubMed Web of Science ®Google Scholar
• Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100(8):1403–1407.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu H, Sun L, et al. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem. 2012;114(6):547–552.
   PubMed Web of Science ®Google Scholar
• Ning S, Bin C, Na H, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep. 2012;39(1):351–357.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen H, Wu X, et al. The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Manag Res. 2019;11:2935–2946.
   PubMed Web of Science ®Google Scholar
• Ye X, Li G, Han C, et al. Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma. Cancer Manag Res. 2018;10:5639–5647.
   PubMed Web of Science ®Google Scholar
• N’Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology. 2009;50(5):1475–1483.
   PubMed Web of Science ®Google Scholar
• Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–328.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Y, Li Q, et al. Radiofrequency ablation versus surgical resection for intrahepatic hepatocellular carcinoma recurrence: a meta-analysis. J Surg Res. 2015;195(1):166–174.
   PubMed Web of Science ®Google Scholar
• Bai H, Huangz X, Jing L, et al. The effect of radiofrequency ablation vs. liver resection on survival outcome of colorectal liver metastases (CRLM): a meta-analysis. Hepatogastroenterology. 2015;62(138):373–377.
   PubMedGoogle Scholar
• Feng Q, Chi Y, Liu Y, et al. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol. 2015;141(1):1–9.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Marisi G, Canale M, et al. Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. Onco Targets Ther. 2018;11:6555–6567.
   PubMed Web of Science ®Google Scholar
• Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018;129:44–53.
   PubMed Web of Science ®Google Scholar
• Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014 Jan;29(1):157–164.
   PubMed Web of Science ®Google Scholar
• Lee S, Rhim H, Kim YS, et al. Post-ablation des-gammacarboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int. 2016;36(4):580–587.
   PubMed Web of Science ®Google Scholar
• Sohn W, Choi MS, Cho JY, et al. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Gut Liver. 2014;8(5):543–551.
   PubMed Web of Science ®Google Scholar
• Kao WY, Chiou YY, Hung HH, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol. 2012;67:429–436.
   PubMed Web of Science ®Google Scholar
• Kusaba T. Relationship between Lens culinaris agglutinin reactive alphafetoprotein and biological features of hepatocellular carcinoma. Kurume Med J. 1998;45(1):113–120.
   PubMedGoogle Scholar
• Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44(6):1518–1527.
   PubMed Web of Science ®Google Scholar
• Takada H, Tsuchiya K, Yasui Y, et al. Irregular vascular pattern by contrastenhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular. Cancer Med. 2016;5(11):3111–3120.
   PubMed Web of Science ®Google Scholar
• Ueno M, Hayami S, Shigekawa Y, et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤5 cm: cohort study based on serum HCC markers. J Hepatol. 2015;63(6):1352–1359.
   PubMed Web of Science ®Google Scholar
• Asaoka Y, Tateishi R, Nakagomi R, et al. Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma. PLoS One. 2014;9(11):e111662. Published 2014 Nov 14.
   PubMed Web of Science ®Google Scholar
• Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–578.
   PubMed Web of Science ®Google Scholar
• Okuwaki Y, Nakazawa T, Shibuya A, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol. 2008;43(1):71–78.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115(3):571–580.
   PubMed Web of Science ®Google Scholar
• Gu T, Ge Y, Song Y, et al. Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma. Scand J Clin Lab Invest. 2015;75(7):621–627.
   PubMed Web of Science ®Google Scholar
• Erinjeri JP, Thomas CT, Samoilia A, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol. 2013;24(8):1105–1112.
   PubMed Web of Science ®Google Scholar
• Haen SP, Gouttefangeas C, Schmidt D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones. 2011;16(5):495–504.
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-Cell response. Gastroenterology. 2010;138(5):1931–1942.e2.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22(5):1173–1184.
   PubMed Web of Science ®Google Scholar
• Ah Chung H, Kim JH, Hwang Y, et al. Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation. Saudi J Gastroenterol. 2016 Jan-Feb;22(1):57–63.
   Web of Science ®Google Scholar
• Chen TM, Lin CC, Huang PT, et al. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553–561.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim JK, Nam JS, et al. High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem. 2015;48(16–17):1073–1078.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim SS, Nam JS, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol. 2016;41(2):181–189.
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163.e2.
   PubMed Web of Science ®Google Scholar
• Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352–360.
   PubMed Web of Science ®Google Scholar
• Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–1721.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Tamburini E, Iñarrairaegui M, et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018;11:7315–7321. Published 2018 Oct 25.
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636.
   PubMed Web of Science ®Google Scholar
• Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921.
   PubMed Web of Science ®Google Scholar
• Ali R, Yang Y, Antkowiak M, et al. Prognosticating survival in hepatocellular carcinoma with elevated baseline alpha-fetoprotein treated with radioembolization using a novel laboratory scoring system: initial development and validation. Cardiovasc Intervent Radiol. 2019;42(5):700–711.
   PubMed Web of Science ®Google Scholar
• Antkowiak M, Gabr A, Das A, et al. Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers (Basel). 2019;11(6):879. Published 2019 Jun 24.
   PubMed Web of Science ®Google Scholar
• Gui B, Weiner AA, Nosher J, et al. Assessment of the Albumin-Bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. Am J Clin Oncol. 2018;41(9):861–866.
   PubMed Web of Science ®Google Scholar
• Hickey R, Mouli S, Kulik L, et al. Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27(6):795–802.
   PubMed Web of Science ®Google Scholar
• Seidensticker M, Powerski M, Seidensticker R, et al. Cytokines and 90Y-radioembolization: relation to liver function and overall survival. Cardiovasc Intervent Radiol. 2017;40(8):1185–1195.
   PubMed Web of Science ®Google Scholar
• Taussig MD, Irene Koran ME, Mouli SK, et al. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. HPB (Oxford). 2017;19(5):458–464.
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171.
   PubMed Web of Science ®Google Scholar
• Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol. 2010;194(3):830–837.
   PubMed Web of Science ®Google Scholar
• Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413–420.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Santini D, Aprile G, et al. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget. 2017;8(39):66699–66708. Published 2017 Jul 22.
   PubMedGoogle Scholar
• Kohles N, Nagel D, Jüngst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33–40.
   PubMed Web of Science ®Google Scholar
• Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734–5742.
   PubMed Web of Science ®Google Scholar
• Lee YK, Kim SU, Kim Do Y, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5.
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Yang SH, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol. 2002;35:398–402.
   PubMed Web of Science ®Google Scholar
• Huang C, Sheng S, Sun X, et al. Lens culinaris agglutinin-reactive α-fetoprotein decline after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma predicts survival. Clin Chim Acta. 2014;431:232–238.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang X, Liu J. Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis. PLoS One. 2019;14(11):e0225170. Published 2019 Nov 15.
   PubMedGoogle Scholar
• Poon RT, Lau C, Yu WC, et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004;11:1077–1084.
   PubMed Web of Science ®Google Scholar
• Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–2882.
   PubMed Web of Science ®Google Scholar
• Hsieh MY, Lin ZY, Chuang WL. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung J Med Sci. 2011;27:314–322.
   PubMed Web of Science ®Google Scholar
• Zheng YB, Meng QW, Zhao W, et al. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014;31:843.
   PubMed Web of Science ®Google Scholar
• Choi KS, Bae MK, Jeong JW, et al. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol. 2003;36:120–127.
   PubMedGoogle Scholar
• Jia ZZ, Jiang GM, Feng YL. Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2011;26:158–162.
   PubMedGoogle Scholar
• Liu J, Yan J, Zhou C, et al. miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma. Tumour Biol. 2015;36(1):219–225.
   PubMedGoogle Scholar
• Liu M, Liu J, Wang L, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One. 2014;9(10):e109347.
   PubMed Web of Science ®Google Scholar
• Suehiro T, Miyaaki H, Kanda Y, et al. Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. Oncol Lett. 2018;16(3):3267–3273.
   PubMed Web of Science ®Google Scholar
• Xiao WK, Chen D, Li SQ, et al. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14:117.
   PubMed Web of Science ®Google Scholar
• Xu X, Chen W, Zhang L, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin Med J (Engl). 2014;127:4204–4209.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res. 2012;160:146–152.
   PubMed Web of Science ®Google Scholar
• Ayaru L, Pereira SP, Alisa A, et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914–1922.
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang B, Huang ZL, et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. PLoS One. 2013;8:e60444.
   PubMed Web of Science ®Google Scholar
• Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol. 2018;211(5):1026–1034.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Tovoli F, Ielasi L, Casadei-Gardini A, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019;71(6):1175–1183.
   PubMed Web of Science ®Google Scholar
• Brunetti O, Gnoni A, Licchetta A, et al. Predictive and prognostic factors in HCC patients treated with sorafenib. Medicina (Kaunas). 2019;55(10):707. Published 2019 Oct 21.
   PubMed Web of Science ®Google Scholar
• Rovesti G, Orsi G, Kalliopi A, et al. Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience. Gastrointest Tumors. 2019;6(3–4):92–107.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Scarpi E, Foschi FG, et al. Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. Clin Res Hepatol Gastroenterol. 2019;43(5):e76–e78.
   PubMed Web of Science ®Google Scholar
• Marisi G, Cucchetti A, Ulivi P, et al. Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers?. World J Gastroenterol. 2018;24(36):4152–4163.
   PubMed Web of Science ®Google Scholar
• Di Costanzo GG, Casadei Gardini A, Marisi G, et al. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Target Oncol. 2017;12(6):795–803.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Chiadini E, Faloppi L, et al. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer. 2016 [Published 2016 Jul 7];16:429.
   PubMed Web of Science ®Google Scholar
• Faloppi L, Bianconi M, Memeo R, et al. Lactate dehydrogenase in hepatocellular carcinoma: something old, something new. Biomed Res Int. 2016;2016:7196280.
   PubMedGoogle Scholar
• Casadei Gardini A, Scarpi E, Marisi G, et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget. 2016;7(12):15243–15251.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Cucchetti A, Cammà C, et al. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol. 2019;15(29):3411–3422.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Solaini L, Riggi L, et al. Prognostic Role of a New Index (RAPID Index) in advanced hepatocellular carcinoma patients receiving sorafenib: training and validation cohort. Gastrointest Tumors. 2019;6(3–4):71–80.
   PubMed Web of Science ®Google Scholar
• Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009;11:111–116.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CE, Lathia CD, et al. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–2300.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Tomoda T, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1604–1611.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer. 2014;120:229–237.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135:1247–1256.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Marisi G, Faloppi L, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016;7:27988–27999.
   PubMed Web of Science ®Google Scholar
• Marisi G, Scartozzi M, Faloppi L, et al. Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. J Clin Oncol. 2017;35(Suppl 15):e15666.
   Google Scholar
• Casadei Gardini A, Marisi G, Dadduzio V, et al. Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: final results of INNOVATE study. Ann Oncol. 2019 October;30(Supplement_5):mdz247.074.
   Google Scholar
• Gardini AC, Faloppi L, Aprile G, et al. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori. 2018;104(6):476–479.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Scarpi E, Faloppi L, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7:67142–67149.
   PubMedGoogle Scholar
• Howell J, Pinato DJ, Ramaswami R, et al. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8:36161–36170.
   PubMedGoogle Scholar
• da Fonseca LG, Barroso-Sousa R, Bento Ada S, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264.
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008.
   PubMed Web of Science ®Google Scholar
• Vaira V, Roncalli M, Carnaghi C, et al. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int. 2015;35:1077–1086.
   PubMed Web of Science ®Google Scholar
• Gyöngyösi B, Végh É, Járay B, et al. Pretreatment MicroRNA level and outcome in sorafenib-treated hepatocellular carcinoma. J Histochem Cytochem. 2014;62:547–555.
   PubMed Web of Science ®Google Scholar
• Fornari F, Pollutri D, Patrizi C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of Caspase-3-mediated apoptosis. Clin Cancer Res. 2017;23:3953–3965.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase III non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–88.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol. 2017;35:4073.
   Web of Science ®Google Scholar
• Sangro B, Yau T, Crocenzi TS, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Cheng A-L, et al. LBA30 Analysis of serum biomarkers (BM) in patients (PTS) from a Phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Ann Oncol. 2017;28(suppl_5).
   Google Scholar
• Casadei Gardini A, Puzzoni M, Montagnani F, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981–2988.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Frassineti GL, Foschi FG, et al. and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: analysis of RESORCE and SHARP trials. Dig Liver Dis. 2017;49(8):943–944.
   PubMedGoogle Scholar
• Teufel M, Seidel H, Kochert K, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156(6):1731–1741.
   PubMed Web of Science ®Google Scholar
• Ressom HW, Di Poto C, Ferrarini A, et al. Multi-omic approaches for characterization of hepatocellular carcinoma. Conf Proc IEEE Eng Med Biol Soc. 2016;2016:3437–3440. DOI: 10.1109/EMBC.2016.7591467
   PubMedGoogle Scholar
• Nie W, Yan L, Lee YH, et al. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrom Rev. 2016;35(3):331–349.
   PubMed Web of Science ®Google Scholar
• Zhang Z. Genomic landscape of liver cancer. Nat Genet. 2012;44(10):1075–1077.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342(2):223–230.
   PubMed Web of Science ®Google Scholar
• Bárcena-Varela M, Caruso S, Llerena S, et al. Dual targeting of histone methyltransferase G9a and DNA-Methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 2019;69(2):587–603.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou J, Li J, et al. Plasma metabolomic analysis of human hepatocellular carcinoma: diagnostic and therapeutic study. Oncotarget. 2016;7(30):47332–47342.
   PubMedGoogle Scholar
• Di Poto C, Ferrarini A, Zhao Y, et al. Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery. Cancer Epidemiol Biomarkers Prev. 2017;26(5):675–683.
   PubMed Web of Science ®Google Scholar
• Fages A, Duarte-Salles T, Stepien M, et al. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med. 2015 [Published 2015 Sep 23];13:242.
   PubMed Web of Science ®Google Scholar
• Del Coco L, Vergara D, De Matteis S, et al. NMR-Based metabolomic approach tracks potential serum biomarkers of disease progression in patients with Type 2 diabetes mellitus. J Clin Med. 2019;8(5):720.
   Web of Science ®Google Scholar
• De Matteis S, Ragusa A, Marisi G, et al. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Oxid Med Cell Longev. 2018;2018:7512159.
   PubMed Web of Science ®Google Scholar
• Yan J, Risacher SL, Shen L, et al. Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. Brief Bioinform. 2018;19(6):1370–1381.
   PubMed Web of Science ®Google Scholar
• Davnall F, Yip CS, Ljungqvist G, et al. Assessment of Tumor Heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3(6):573–589.
   PubMedGoogle Scholar
• Ganeshan B, Miles KA. Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013;13(1):140–149.
   PubMed Web of Science ®Google Scholar
• Lubner MG, Smith AD, Sandrasegaran K, et al. CT texture analysis: definitions, applications, biologic correlates, and challenges. RadioGraphics. 2017;37:1483–1503.
   PubMed Web of Science ®Google Scholar
• Bodalal Z, Trebeschi S, Nguyen-Kim TDL, et al. Radiogenomics: bridging imaging and genomics. Abdom Radiol. 2019;44:1960–1984.
   PubMed Web of Science ®Google Scholar
• Kiryu S, Akai H, Nojima M, et al. Impact of hepatocellular carcinoma heterogeneity on computed tomography as a prognostic indicator. Sci Rep. 2017;7(1):12689.
   PubMedGoogle Scholar
• Saini A, Breen I, Pershad Y, et al. Radiogenomics and radiomics in liver cancers. Diagnostics. 2019;9(1):4.
   Web of Science ®Google Scholar
• Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2017;42(6):1695–1704.
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484.
   PubMed Web of Science ®Google Scholar
• Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114.
   PubMed Web of Science ®Google Scholar
• Okajima W, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2017;23(31):5650–5668.
   PubMed Web of Science ®Google Scholar
• Zocco D, Ferruzzi P, Cappello F, et al. Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Front Oncol. 2014;4:267.
   PubMedGoogle Scholar
• Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biological function and clinical potential. Cell Biosci. 2019;9:19.
   PubMed Web of Science ®Google Scholar
• MJ S, Szajnik M, Welsh A, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96:1302–1309.
   PubMed Web of Science ®Google Scholar
• Dabitao D, Margolick JB, Lopez J, et al. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J Immunol Methods. 2011;372:71–77.
   PubMed Web of Science ®Google Scholar
• Milane L, Singh A, Mattheolabakis G, et al. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–294.
   PubMed Web of Science ®Google Scholar
• Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 2013;15:281–295.
   PubMed Web of Science ®Google Scholar
• Ciardiello C, Cavallini L, Spinelli C, et al. Focus on extracellular vesicles: new frontiers of Cell-to-Cell communication in cancer. Int J Mol Sci. 2016;17:175.
   PubMed Web of Science ®Google Scholar